Approval Package for:

APPLICATION NUMBER:

NDA 019853Orig1s014

Trade Name: Cuprimine

Generic Name: Penicillamine

Sponsor: Merck & Co. Inc

Approval Date: October 26, 2004

Indication: • Treatment of Wilson’s disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Contents

Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Approval Letter</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Action Letters</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td></td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td>X</td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
NDA 19-853/S-012 & 014

Merck & Co., Inc.
Attention: Kenneth A. Kramer
Manager, Regulatory Affairs
Sunnymontown Pike
P.O. Box 4, BLA-20
West Point, PA 19486

Dear Mr. Kramer:

Please refer to your supplemental new drug application 012 dated August 22, 2002, received August 23, 2002 and supplemental new drug application 014 dated July 14, 2004, received July 15, 2004 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cuprimine (penicillamine) Capsules 125 mg and 250 mg.

We acknowledge receipt of your submission dated July 08, 2004 for supplement 012.

Your submission of April 23, 2004 constituted a complete response to our October 08, 2003 action letter for supplement 012. We acknowledge that this is the first review cycle for supplement 014.

Supplemental new drug application 012 provides for a new subsection titled “Geriatric Use” which has been added to include information regarding the use of Cuprimine in the elderly. Pharmacokinetic data have been added under CLINICAL PHARMACOLOGY to support the new “Geriatric Use” text regarding renal excretion.

Supplemental new drug application 014 provides the following changes:

- WARNINGS, Pregnancy – adding category statement, Category D and pregnancy text elements referenced in 21 CFR 201.57(f)(6)(d);

- PRECAUTIONS, Carcinogenesis – revisions to “Carcinogenesis, Mutagenesis, Impairment of Fertility” and text about the mutagenic effect of penicillamine

- PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility and text about the mutagenic effect of penicillamine

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling.
The electronic labeling rule published December 11, 2003, (68 FR 69009) requires submission of labeling content in electronic format effective June 8, 2004. For additional information, consult the following guidances for industry regarding electronic submissions: Providing Regulatory Submissions in Electronic Format - NDAs (January 1999) and Providing Regulatory Submissions in Electronic Format – Content of Labeling (February 2004). The guidances specify that labeling to be submitted in pdf format. To assist in our review, we request that labeling also be submitted in MS Word format. If formatted copies of all labeling pieces (i.e., package insert, patient package insert, container labels, and carton labels) are submitted electronically, labeling does not need to be submitted in paper.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Barbara Gould, Regulatory Project Manager, at (301) 827-2506.

Sincerely,

{See appended electronic signature page}

Sharon Hertz, M.D.
Deputy Director
Division of Anti-Inflammatory, Analgesic, & Ophthalmic Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Sharon Hertz
10/26/04 06:19:57 PM
CAPSULES
CUPRIMINE®
(PENCILLAMINE)

Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.

DESCRIPTION

Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy (see INDICATIONS). It is 3-mercapto-D-valine. It is a white or practically white, crystalline powder, freely soluble in water, slightly soluble in alcohol, and insoluble in ether, acetone, benzene, and carbon tetrachloride. Although its configuration is D, it is levorotatory as usually measured:

\[
\alpha \quad 25^\circ = \pm 62.5^\circ \pm 2^\circ \quad (c = 1, \; 1N \; \text{NaOH}),
\]

D

calculated on a dried basis.

The empirical formula is C₆H₁₁NO₂S, giving it a molecular weight of 149.21. The structural formula is:

\[
\text{SH} \quad \text{NH}_2
\]

\[
\text{(CH}_3\text{)}_2\text{C} \longrightarrow \text{CHCOOH}
\]

It reacts readily with formaldehyde or acetone to form a thiazolidine-carboxylic acid.

Capsules CUPRIMINE® (Penicillamine) for oral administration contain either 125 mg or 250 mg of penicillamine. Each capsule contains the following inactive ingredients: D & C Yellow 10, gelatin, lactose, magnesium stearate, and titanium dioxide. The 125 mg capsule also contains iron oxide.

CLINICAL PHARMACOLOGY

Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson’s disease. From in vitro studies which indicate that one atom of copper combines with two molecules of penicillamine, it would appear that one gram of penicillamine should be followed by the excretion of about 200 milligrams of copper; however, the actual amount excreted is about one percent of this.

Penicillamine also reduces excess cystine excretion in cystinuria. This is done, at least in part, by disulfide interchange between penicillamine and cystine, resulting in formation of penicillamine-cysteine disulfide, a substance that is much more soluble than cystine and is excreted readily.

Penicillamine interferes with the formation of cross-links between tropocollagen molecules and cleaves them when newly formed.

The mechanism of action of penicillamine in rheumatoid arthritis is unknown although it appears to suppress disease activity. Unlike cytotoxic immunosuppressants, penicillamine markedly lowers IgM rheumatoid factor but produces no significant depression in absolute levels of serum immunoglobulins. Also unlike cytotoxic immunosuppressants which act on both, penicillamine in vitro depresses T-cell activity but not B-cell activity.

In vitro, penicillamine dissociates macroglobulins (rheumatoid factor) although the relationship of the activity to its effect in rheumatoid arthritis is not known.
In rheumatoid arthritis, the onset of therapeutic response to CUPRIMINE may not be seen for two or three months. In those patients who respond, however, the first evidence of suppression of symptoms such as pain, tenderness, and swelling is generally apparent within three months. The optimum duration of therapy has not been determined. If remissions occur, they may last from months to years, but usually require continued treatment (see DOSAGE AND ADMINISTRATION).

In all patients receiving penicillamine, it is important that CUPRIMINE be given on an empty stomach, at least one hour before meals or two hours after meals, and at least one hour apart from any other drug, food, milk, antacid, zinc or iron-containing preparation. This permits maximum absorption and reduces the likelihood of inactivation by metal binding in the gastrointestinal tract.

**Pharmacokinetics**

Penicillamine is absorbed rapidly but incompletely (40-70%) from the gastrointestinal tract, with wide inter-individual variations. Food, antacids, and iron reduce absorption of the drug. The peak plasma concentration of penicillamine occurs 1-3 hours after ingestion; it is approximately 1-2 mg/L after an oral dose of 250 mg. The drug appears in the plasma as free penicillamine, penicillamine disulfide, and cysteine-penicillamine disulfide. When prolonged treatment is stopped, there is a slow elimination phase lasting 4-6 days.

More than 80% of plasma penicillamine is bound to proteins, especially albumin and ceruloplasmin. The drug also binds to erythrocytes and macrophages. A small fraction of the dose is metabolized in the liver to S-methyl-D-penicillamine. Excretion is mainly renal, mainly as disulfides.

**INDICATIONS**

CUPRIMINE is indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that CUPRIMINE is not of value in ankylosing spondylitis.

**Wilson's Disease** — Wilson's disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology.

Two types of patients require treatment for Wilson's disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated.

The diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is <20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (>250 mcg/g dry weight) or Kayser-Fleischer rings are present.

Treatment has two objectives:

(1) to minimize dietary intake of copper;

(2) to promote excretion and complex formation (i.e., detoxification) of excess tissue copper.

The first objective is attained by a daily diet that contains no more than one or two milligrams of copper. Such a diet should exclude, most importantly, chocolate, nuts, shellfish, mushrooms, liver, molasses, broccoli, and cereals and dietary supplements enriched with copper, and be composed to as great an extent as possible of foods with a low copper content. Distilled or demineralized water should be used if the patient's drinking water contains more than 0.1 mg of copper per liter.

For the second objective, a copper chelating agent is used.

In symptomatic patients this treatment usually produces marked neurologic improvement, fading of Kayser-Fleischer rings, and gradual amelioration of hepatic dysfunction and psychic disturbances. Clinical experience to date suggests that life is prolonged with the above regimen.

Noticeable improvement may not occur for one to three months. Occasionally, neurologic symptoms become worse during initiation of therapy with CUPRIMINE. Despite this, the drug should not be withdrawn. Temporary

interruption carries an increased risk of developing a sensitivity reaction upon resumption of therapy, although it may result in clinical improvement of neurological symptoms (see WARNINGS). If the neurological symptoms and signs continue to worsen for a month after the initiation of CUPRIMINE therapy, several short courses of treatment with 2,3-dimercaprol (BAL) while continuing CUPRIMINE may be considered.

Treatment of asymptomatic patients has been carried out for over thirty years. Symptoms and signs of the disease appear to be prevented indefinitely if daily treatment with CUPRIMINE is continued.

_Cystinuria_ — Cystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal, recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: (1) defective gastrointestinal absorption and (2) renal tubular dysfunction.

Arginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities.

Cystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria.

Normal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated.

Conventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see PRECAUTIONS).

When these measures are inadequate to control recurrent stone formation, CUPRIMINE may be used as additional therapy, and when patients refuse to adhere to conventional treatment, CUPRIMINE may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients.

Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillamine-cysteine mixed disulfide as:

\[
\begin{align*}
\text{CSSC} + \text{PS}^-' & \leftrightarrow \text{CS}^-' + \text{CSSP} \\
\text{PSSP} + \text{CS}' & \leftrightarrow \text{PS}' + \text{CSSP} \\
\text{CSSC} + \text{PSSP}^-' & \leftrightarrow 2\text{CSSP} \\
\end{align*}
\]

CSSC = cystine  
CS' = deprotonated cysteine  
PSSP = penicillamine disulfide  
PS' = deprotonated penicillamine sulfhydryl  
CSSP = penicillamine-cysteine mixed disulfide

In this process, it is assumed that the deprotonated form of penicillamine, PS', is the active factor in bringing about the disulfide interchange.

_Rheumatoid Arthritis_ — Because CUPRIMINE can cause severe adverse reactions, its use in rheumatoid arthritis should be restricted to patients who have severe, active disease and who have failed to respond to an adequate trial of conventional therapy. Even then, benefit-to-risk ratio should be carefully considered. Other measures, such as rest, physiotherapy, salicylates, and corticosteroids should be used, when indicated, in conjunction with CUPRIMINE (see PRECAUTIONS).
CONTRAINDICATIONS

Except for the treatment of Wilson's disease or certain patients with cystinuria, use of penicillamine during pregnancy is contraindicated (see WARNINGS).

Although breast milk studies have not been reported in animals or humans, mothers on therapy with penicillamine should not nurse their infants.

Patients with a history of penicillamine-related aplastic anemia or agranulocytosis should not be restarted on penicillamine (see WARNINGS and ADVERSE REACTIONS).

Because of its potential for causing renal damage, penicillamine should not be administered to rheumatoid arthritis patients with a history or other evidence of renal insufficiency.

WARNINGS

The use of penicillamine has been associated with fatalities due to certain diseases such as aplastic anemia, agranulocytosis, Goodpasture's syndrome, and myasthenia gravis.

Because of the potential for serious hematological and renal adverse reactions to occur at any time, routine urinalysis, white and differential blood cell count, hemoglobin determination, and direct platelet count must be done twice weekly, together with monitoring of the patient's skin, lymph nodes and body temperature, during the first month of therapy, every two weeks for the next five months, and monthly thereafter. Patients should be instructed to report promptly the development of signs and symptoms of granulocytopenia and/or thrombocytopenia such as fever, sore throat, chills, bruising or bleeding. The above laboratory studies should then be promptly repeated.

Leukopenia and thrombocytopenia have been reported to occur in up to five percent of patients during penicillamine therapy. Leukopenia is of the granulocytic series and may or may not be associated with an increase in eosinophils. A confirmed reduction in WBC below 3500/mm³ mandates discontinuance of penicillamine therapy. Thrombocytopenia may be on an idiosyncratic basis, with decreased or absent megakaryocytes in the marrow, when it is part of an aplastic anemia. In other cases the thrombocytopenia is presumably on an immune basis since the number of megakaryocytes in the marrow has been reported to be normal or sometimes increased. The development of a platelet count below 100,000/mm³, even in the absence of clinical bleeding, requires at least temporary cessation of penicillamine therapy. A progressive fall in either platelet count or WBC in three successive determinations, even though values are still within the normal range, likewise requires at least temporary cessation.

Proteinuria and/or hematuria may develop during therapy and may be warning signs of membranous glomerulopathy which can progress to a nephrotic syndrome. Close observation of these patients is essential. In some patients the proteinuria disappears with continued therapy; in others, penicillamine must be discontinued. When a patient develops proteinuria or hematuria the physician must ascertain whether it is a sign of drug-induced glomerulopathy or is unrelated to penicillamine.

Rheumatoid arthritis patients who develop moderate degrees of proteinuria may be continued cautiously on penicillamine therapy, provided that quantitative 24-hour urinary protein determinations are obtained at intervals of one to two weeks. Penicillamine dosage should not be increased under these circumstances. Proteinuria which exceeds 1 g/24 hours, or proteinuria which is progressively increasing, requires either discontinuance of the drug or a reduction in the dosage. In some patients, proteinuria has been reported to clear following reduction in dosage.

In rheumatoid arthritis patients penicillamine should be discontinued if unexplained gross hematuria or persistent microscopic hematuria develops.

In patients with Wilson's disease or cystinuria the risks of continued penicillamine therapy in patients manifesting potentially serious urinary abnormalities must be weighed against the expected therapeutic benefits.

When penicillamine is used in cystinuria, an annual x-ray for renal stones is advised. Cystine stones form rapidly, sometimes in six months.

Up to one year or more may be required for any urinary abnormalities to disappear after penicillamine has been discontinued.

Because of rare reports of intrahepatic cholestasis and toxic hepatitis, liver function tests are recommended every six months for the duration of therapy. In Wilson's disease, these are recommended every three months, at least during the first year of treatment.

Goodpasture's syndrome has occurred rarely. The development of abnormal urinary findings associated with hemoptysis and pulmonary infiltrates on x-ray requires immediate cessation of penicillamine.
Obliterative bronchiolitis has been reported rarely. The patient should be cautioned to report immediately pulmonary symptoms such as exertional dyspnea, unexplained cough or wheezing. Pulmonary function studies should be considered at that time.

Onset of new neurological symptoms has been reported with CUPRIMINE (see ADVERSE REACTIONS). Occasionally, neurological symptoms become worse during initiation of therapy with CUPRIMINE (see INDICATIONS). Myasthenic syndrome sometimes progressing to myasthenia gravis has been reported. Ptosis and diplopia, with weakness of the extraocular muscles, are often early signs of myasthenia. In the majority of cases, symptoms of myasthenia have receded after withdrawal of penicillamine.

Most of the various forms of pemphigus have occurred during treatment with penicillamine. Pemphigus vulgaris and pemphigus foliaceus are reported most frequently, usually as a late complication of therapy. The seborrhea-like characteristics of pemphigus foliaceus may obscure an early diagnosis. When pemphigus is suspected, CUPRIMINE should be discontinued. Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. Treatment may be required for only a few weeks or months, but may need to be continued for more than a year.

Once instituted for Wilson's disease or cystinuria, treatment with penicillamine should, as a rule, be continued on a daily basis. Interruptions for even a few days have been followed by sensitivity reactions after reinstitution of therapy.

Pregnancy Category D

Penicillamine can cause fetal harm when administered to a pregnant woman. Penicillamine has been shown to be teratogenic in rats when given in doses 6 times higher than the highest dose recommended for human use. Skeletal defects, cleft palates and fetal toxicity (resorptions) have been reported.

There are no controlled studies on the use of penicillamine in pregnant women. Although normal outcomes have been reported, characteristic congenital cutis laxa and associated birth defects have been reported in infants born of mothers who received therapy with penicillamine during pregnancy. Penicillamine should be used in women of childbearing potential only when the expected benefits outweigh the possible hazards. Women on therapy with penicillamine who are of childbearing potential should be apprised of this risk, advised to report promptly any missed menstrual periods or other indications of possible pregnancy, and followed closely for early recognition of pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Wilson's Disease — Reported experience*** shows that continued treatment with penicillamine throughout pregnancy protects the mother against relapse of the Wilson's disease, and that discontinuation of penicillamine has deleterious effects on the mother, which may be fatal.

If penicillamine is administered during pregnancy to patients with Wilson's disease, it is recommended that the daily dosage be limited to 750 mg. If cesarean section is planned the daily dose should be reduced to 250 mg, but not lower, for the last six weeks of pregnancy and postoperatively until wound healing is complete.

Cystinuria — If possible, penicillamine should not be given during pregnancy to women with cystinuria (see CONTRAINDICATIONS). There are reports of women with cystinuria on therapy with penicillamine who gave birth to infants with generalized connective tissue defects who died following abdominal surgery. If stones continue to form in these patients, the benefits of therapy to the mother must be evaluated against the risk to the fetus.

Rheumatoid Arthritis — Penicillamine should not be administered to rheumatoid arthritis patients who are pregnant (see CONTRAINDICATIONS) and should be discontinued promptly in patients in whom pregnancy is suspected or diagnosed.

There is a report that a woman with rheumatoid arthritis treated with less than one gram a day of penicillamine during pregnancy gave birth (cesarean delivery) to an infant with growth retardation, flattened face with broad nasal bridge, low set ears, short neck with loose skin folds, and unusually lax body skin.

PRECAUTIONS

Some patients may experience drug fever, a marked febrile response to penicillamine, usually in the second to third week following initiation of therapy. Drug fever may sometimes be accompanied by a macular cutaneous eruption.

In the case of drug fever in patients with Wilson's disease or cystinuria, penicillamine should be temporarily discontinued until the reaction subsides. Then penicillamine should be re instituted with a small dose that is

gradually increased until the desired dosage is attained. Systemic steroid therapy may be necessary, and is usually helpful, in such patients in whom drug fever and rash develop several times.

In the case of drug fever in rheumatoid arthritis patients, because other treatments are available, penicillamine should be discontinued and another therapeutic alternative tried since experience indicates that the febrile reaction will recur in a very high percentage of patients upon readministration of penicillamine.

The skin and mucous membranes should be observed for allergic reactions. Early and late rashes have occurred. Early rash occurs during the first few months of treatment and is more common. It is usually a generalized pruritic, erythematous, maculopapular or morbilliform rash and resembles the allergic rash seen with other drugs. Early rash usually disappears within days after stopping penicillamine and seldom recurs when the drug is restarted at a lower dosage. Pruritus and early rash may often be controlled by the concomitant administration of antihistamines. Less commonly, a late rash may be seen, usually after six months or more of treatment, and requires discontinuation of penicillamine. It is usually on the trunk, is accompanied by intense pruritus, and is usually unresponsive to topical corticosteroid therapy. Late rash may take weeks to disappear after penicillamine is stopped and usually recurs if the drug is restarted.

The appearance of a drug eruption accompanied by fever, arthralgia, lymphadenopathy or other allergic manifestations usually requires discontinuation of penicillamine.

Certain patients will develop a positive antinuclear antibody (ANA) test and some of these may show a lupus erythematous-like syndrome similar to drug-induced lupus associated with other drugs. The lupus erythematous-like syndrome is not associated with hypocomplementemia and may be present without nephropathy. The development of a positive ANA test does not mandate discontinuance of the drug; however, the physician should be alerted to the possibility that a lupus erythematous-like syndrome may develop in the future.

Some patients may develop oral ulcerations which in some cases have the appearance of aphthous stomatitis. The stomatitis usually recurs on rechallenge but often clears on a lower dosage. Although rare, cheilosis, glossitis and gingivostomatitis have also been reported. These oral lesions are frequently dose-related and may preclude further increase in penicillamine dosage or require discontinuation of the drug.

Hypogeusia (a blunting or diminution in taste perception) has occurred in some patients. This may last two to three months or more and may develop into a total loss of taste; however, it is usually self-limited despite continued penicillamine treatment. Such taste impairment is rare in patients with Wilson's disease.

Penicillamine should not be used in patients who are receiving concurrently gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone or phenylbutazone because these drugs are also associated with similar serious hematologic and renal adverse reactions. Patients who have had gold salt therapy discontinued due to a major toxic reaction may be at greater risk of serious adverse reactions with penicillamine but not necessarily of the same type.

Patients who are allergic to penicillin may theoretically have cross-sensitivity to penicillamine. The possibility of reactions from contamination of penicillamine by trace amounts of penicillin has been eliminated now that penicillamine is being produced synthetically rather than as a degradation product of penicillin.

Patients with Wilson's disease or cystinuria should be given 25 mg/day of pyridoxine during therapy, since penicillamine increases the requirement for this vitamin. Patients also may receive benefit from a multivitamin preparation, although there is no evidence that deficiency of any vitamin other than pyridoxine is associated with penicillamine. In Wilson's disease, multivitamin preparations must be copper-free.

Rheumatoid arthritis patients whose nutrition is impaired should also be given a daily supplement of pyridoxine. Mineral supplements should not be given, since they may block the response to penicillamine.

Iron deficiency may develop, especially in pediatric patients and in menstruating women. In Wilson's disease, this may be a result of adding the effects of the low copper diet, which is probably also low in iron, and the penicillamine to the effects of blood loss or growth. In cystinuria, a low methionine diet may contribute to iron deficiency, since it is necessarily low in protein. If necessary, iron may be given in short courses, but a period of two hours should elapse between administration of penicillamine and iron, since orally administered iron has been shown to reduce the effects of penicillamine.

Penicillamine causes an increase in the amount of soluble collagen. In the rat this results in inhibition of normal healing and also a decrease in tensile strength of intact skin. In man this may be the cause of increased skin friability at sites especially subject to pressure or trauma, such as shoulders, elbows, knees, toes, and buttocks. Extravasations of blood may occur and may appear as purpuric areas, with external bleeding if the skin is broken, or as vesicles containing dark blood. Neither type is progressive. There is no apparent association with bleeding elsewhere in the body and no associated coagulation defect has been found. Therapy with penicillamine may be continued in the presence of these lesions. They may not recur if dosage is reduced.
Other reported effects probably due to the action of penicillamine on collagen are excessive wrinkling of the skin and development of small, white papules at venipuncture and surgical sites.

The effects of penicillamine on collagen and elastin make it advisable to consider a reduction in dosage to 250 mg/day, when surgery is contemplated. Reinstitution of full therapy should be delayed until wound healing is complete.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term animal carcinogenicity studies have not been done with penicillamine. There is a report that five of ten autoimmune disease-prone NZB hybrid mice developed lymphocytic leukemia after 6 months' intraperitoneal treatment with a dose of 400 mg/kg penicillamine 5 days per week.

Penicillamine is directly mutagenic to *S. typhimurium* strain TA92 in the Ames test; mutagenicity is enhanced by kidney postmitochondrial subcellular fraction 9. Penicillamine does not induce gene mutations in Chinese hamster V79 cells.

Penicillamine induces sister-chromatid exchanges and chromosome aberrations in cultivated mammalian cells. No studies on the effect of penicillamine on fertility are available.

**Pregnancy**

*Pregnancy Category D* (see WARNINGS, Pregnancy)

**Nursing Mothers**

See CONTRAINDICATIONS.

**Pediatric Use**

The efficacy of CUPRIMINE in juvenile rheumatoid arthritis has not been established.

**Geriatric Use**

Clinical studies of CUPRIMINE are limited in subjects aged 65 and over, they did not include sufficient numbers of elderly subjects aged 65 and over to adequately determine whether they respond differently from younger subjects. Review of reported clinical trials with penicillamine in the elderly suggest greater risk than in younger patients for overall skin rash and abnormality of taste. In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drugs.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and careful monitoring of renal function is recommended.

**ADVERSE REACTIONS**

Penicillamine is a drug with a high incidence of untoward reactions, some of which are potentially fatal. Therefore, it is mandatory that patients receiving penicillamine therapy remain under close medical supervision throughout the period of drug administration (see WARNINGS and PRECAUTIONS).

Reported incidences (%) for the most commonly occurring adverse reactions in rheumatoid arthritis patients are noted, based on 17 representative clinical trials reported in the literature (1270 patients).

**Allergic** — Generalized pruritus, early and late rashes (5%), pemphigus (see WARNINGS), and drug eruptions which may be accompanied by fever, arthralgia, or lymphadenopathy have occurred (see WARNINGS and PRECAUTIONS). Some patients may show a lupus erythematosus-like syndrome similar to drug-induced lupus produced by other pharmacological agents (see PRECAUTIONS).

Urticaria and exfoliative dermatitis have occurred.

Thyroiditis has been reported; hypoglycemia in association with anti-insulin antibodies has been reported. These reactions are extremely rare.

Some patients may develop a migratory polyarthralgia, often with objective synovitis (see DOSAGE AND ADMINISTRATION).

**Gastrointestinal** — Anorexia, epigastric pain, nausea, vomiting, or occasional diarrhea may occur (17%).

Isolated cases of reactivated peptic ulcer have occurred, as have hepatic dysfunction including hepatic failure, and pancreatitis. Intrahepatic cholestasis and toxic hepatitis have been reported rarely. There have been a few reports of increased serum alkaline phosphatase, lactic dehydrogenase, and positive cephalin flocculation and thymol turbidity tests.

Some patients may report a blunting, diminution, or total loss of taste perception (12%); or may develop oral ulcerations. Although rare, cheilosis, glossitis, and gingivostomatitis have been reported (see PRECAUTIONS).
Gastrointestinal side effects are usually reversible following cessation of therapy.

**Hematological** — Penicillamine can cause bone marrow depression (see WARNINGS). Leukopenia (2%) and thrombocytopenia (4%) have occurred. Fatalities have been reported as a result of thrombocytopenia, agranulocytosis, aplastic anemia, and sideroblastic anemia.

Thrombotic thrombocytopenic purpura, hemolytic anemia, red cell aplasia, monocytosis, leukocytosis, eosinophilia, and thrombocytosis have also been reported.

**Renal** — Patients on penicillamine therapy may develop proteinuria (6%) and/or hematuria which, in some, may progress to the development of the nephrotic syndrome as a result of an immune complex membranous glomerulopathy (see WARNINGS). Renal failure has been reported.

**Central Nervous System** — Tinnitus, optic neuritis and peripheral sensory and motor neuropathies (including polyradiculoneuropathy, i.e., Guillain-Barré syndrome) have been reported. Muscular weakness may or may not occur with the peripheral neuropathies. Visual and psychic disturbances; mental disorders; and agitation and anxiety have been reported.

**Neuromuscular** — Myasthenia gravis (see WARNINGS); dystonia.

**Other** — Adverse reactions that have been reported rarely include thrombophlebitis; hyperpyrexia (see PRECAUTIONS); falling hair or alopecia; lichen planus; polymyositis; dermatomyositis; mammary hyperplasia; elastosis perforans serpiginosa; toxic epidermal necrolysis; anetoderma (cutaneous macular atrophy); and Goodpasture’s syndrome, a severe and ultimately fatal glomerulonephritis associated with intra-alveolar hemorrhage (see WARNINGS). Vasculitis, including fatal renal vasculitis, has also been reported. Allergic alveolitis, obliterative bronchiolitis, interstitial pneumonitis and pulmonary fibrosis have been reported in patients with severe rheumatoid arthritis, some of whom were receiving penicillamine. Bronchial asthma also has been reported.

Increased skin friability, excessive wrinkling of skin, and development of small white papules at venipuncture and surgical sites have been reported (see PRECAUTIONS); yellow nail syndrome.

The chelating action of the drug may cause increased excretion of other heavy metals such as zinc, mercury and lead.

There have been reports associating penicillamine with leukemia. However, circumstances involved in these reports are such that a cause and effect relationship to the drug has not been established.

**DOSEAGE AND ADMINISTRATION**

In all patients receiving penicillamine, it is important that CUPRIMINE be given on an empty stomach, at least one hour before meals or two hours after meals, and at least one hour apart from any other drug, food, or milk. Because penicillamine increases the requirement for pyridoxine, patients may require a daily supplement of pyridoxine (see PRECAUTIONS).

**Wilson’s Disease** — Optimal dosage can be determined by measurement of urinary copper excretion and the determination of free copper in the serum. The urine must be collected in copper-free glassware, and should be quantitatively analyzed for copper before and soon after initiation of therapy with CUPRIMINE.

Determination of 24-hour urinary copper excretion is of greatest value in the first week of therapy with penicillamine. In the absence of any drug reaction, a dose between 0.75 and 1.5 g that results in an initial 24-hour cupriuresis of over 2 mg should be continued for about three months, by which time the most reliable method of monitoring maintenance treatment is the determination of free copper in the serum. This equals the difference between quantitatively determined total copper and ceruloplasmin-copper. Adequately treated patients will usually have less than 10 mcg free copper/dL of serum. It is seldom necessary to exceed a dosage of 2 g/day. If the patient is intolerant to therapy with CUPRIMINE, alternative treatment is trientine hydrochloride.

In patients who cannot tolerate as much as 1 g/day initially, initiating dosage with 250 mg/day, and increasing gradually to the requisite amount, gives closer control of the effects of the drug and may help to reduce the incidence of adverse reactions.

**Cystinuria** — It is recommended that CUPRIMINE be used along with conventional therapy. By reducing urinary cystine, it decreases crystalluria and stone formation. In some instances, it has been reported to decrease the size of, and even to dissolve, stones already formed.

The usual dosage of CUPRIMINE in the treatment of cystinuria is 2 g/day for adults, with a range of 1 to 4 g/day. For pediatric patients, dosage can be based on 30 mg/kg/day. The total daily amount should be divided into four doses. If four equal doses are not feasible, give the larger portion at bedtime. If adverse reactions necessitate a reduction in dosage, it is important to retain the bedtime dose.
Initiating dosage with 250 mg/day, and increasing gradually to the requisite amount, gives closer control of the effects of the drug and may help to reduce the incidence of adverse reactions.

In addition to taking CUPRIMINE, patients should drink copiously. It is especially important to drink about a pint of fluid at bedtime and another pint once during the night when urine is more concentrated and more acid than during the day. The greater the fluid intake, the lower the required dosage of CUPRIMINE.

Dosage must be individualized to an amount that limits cystine excretion to 100-200 mg/day in those with no history of stones, and below 100 mg/day in those who have had stone formation and/or pain. Thus, in determining dosage, the inherent tubular defect, the patient's size, age, and rate of growth, and his diet and water intake all must be taken into consideration.

The standard nitroprusside cyanide test has been reported useful as a qualitative measure of the effective dose:† Add 2 mL of freshly prepared 5 percent sodium cyanide to 5 mL of a 24-hour aliquot of protein-free urine and let stand ten minutes. Add 5 drops of freshly prepared 5 percent sodium nitroprusside and mix. Cystine will turn the mixture magenta. If the result is negative, it can be assumed that cystine excretion is less than 100 mg/g creatinine.

Although penicillamine is rarely excreted unchanged, it also will turn the mixture magenta. If there is any question as to which substance is causing the reaction, a ferric chloride test can be done to eliminate doubt: Add 3 percent ferric chloride dropwise to the urine. Penicillamine will turn the urine an immediate and quickly fading blue. Cystine will not produce any change in appearance.

**Rheumatoid Arthritis** — The principal rule of treatment with CUPRIMINE in rheumatoid arthritis is patience. The onset of therapeutic response is typically delayed. Two or three months may be required before the first evidence of a clinical response is noted (see CLINICAL PHARMACOLOGY).

When treatment with CUPRIMINE has been interrupted because of adverse reactions or other reasons, the drug should be reintroduced cautiously by starting with a lower dosage and increasing slowly.

**Initial Therapy** — The currently recommended dosage regimen in rheumatoid arthritis begins with a single daily dose of 125 mg or 250 mg, which is thereafter increased at one to three month intervals, by 125 mg or 250 mg/day, as patient response and tolerance indicate. If a satisfactory remission of symptoms is achieved, the dose associated with the remission should be continued (see Maintenance Therapy). If there is no improvement and there are no signs of potentially serious toxicity after two to three months of treatment with doses of 500-750 mg/day, increases of 250 mg/day at two to three month intervals may be continued until a satisfactory remission occurs (see Maintenance Therapy) or signs of toxicity develop (see WARNINGS and PRECAUTIONS). If there is no discernible improvement after three to four months of treatment with 1000 to 1500 mg of penicillamine/day, it may be assumed the patient will not respond and CUPRIMINE should be discontinued.

**Maintenance Therapy** — The maintenance dosage of CUPRIMINE must be individualized, and may require adjustment during the course of treatment. Many patients respond satisfactorily to a dosage within the 500-750 mg/day range. Some need less.

Changes in maintenance dosage levels may not be reflected clinically or in the erythrocyte sedimentation rate for two to three months after each dosage adjustment.

Some patients will subsequently require an increase in the maintenance dosage to achieve maximal disease suppression. In those patients who do respond, but who evidence incomplete suppression of their disease after the first six to nine months of treatment, the daily dosage of CUPRIMINE may be increased by 125 mg or 250 mg/day at three-month intervals. It is unusual in current practice to employ a dosage in excess of 1 g/day, but up to 1.5 g/day has sometimes been required.

**Management of Exacerbations** — During the course of treatment some patients may experience an exacerbation of disease activity following an initial good response. These may be self-limited and can subside within twelve weeks. They are usually controlled by the addition of non-steroidal anti-inflammatory drugs, and only if the patient has demonstrated a true "escape" phenomenon (as evidenced by failure of the flare to subside within this time period) should an increase in the maintenance dose ordinarily be considered.

In the rheumatoid patient, migratory polyarthralgia due to penicillamine is extremely difficult to differentiate from an exacerbation of the rheumatoid arthritis. Discontinuance or a substantial reduction in dosage of CUPRIMINE for up to several weeks will usually determine which of these processes is responsible for the arthralgia.

---

Duration of Therapy — The optimum duration of therapy with CUPRIMINE in rheumatoid arthritis has not been determined. If the patient has been in remission for six months or more, a gradual, stepwise dosage reduction in decrements of 125 mg or 250 mg/day at approximately three month intervals may be attempted.

Concomitant Drug Therapy — CUPRIMINE should not be used in patients who are receiving gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone, or phenylbutazone (see PRECAUTIONS). Other measures, such as salicylates, other non-steroidal anti-inflammatory drugs, or systemic corticosteroids, may be continued when penicillamine is initiated. After improvement commences, analgesic and anti-inflammatory drugs may be slowly discontinued as symptoms permit. Steroid withdrawal must be done gradually, and many months of treatment with CUPRIMINE may be required before steroids can be completely eliminated.

Dosage Frequency — Based on clinical experience, dosages up to 500 mg/day can be given as a single daily dose. Dosages in excess of 500 mg/day should be administered in divided doses.

HOW SUPPLIED

No. 3299 — Capsules CUPRIMINE, 250 mg, are ivory-colored capsules containing a white or nearly white powder, and are coded CUPRIMINE and MSD 602. They are supplied as follows:

NDC 0006-0602-68 in bottles of 100.

No. 3350 — Capsules CUPRIMINE, 125 mg, are opaque ivory and gray capsules containing a white or nearly white powder, and are coded CUPRIMINE and MSD 672. They are supplied as follows:

NDC 0006-0672-68 in bottles of 100.

Storage

Keep container tightly closed.
APPLICATION NUMBER:
NDA 019853Orig1s014

MEDICAL REVIEW(S)
Medical Officer Review  
Division of Anti-inflammatory, Analgesic and Ophthalmic Drug Products  
HFD-550

Date: August 25, 2004

From: Carolyn L. Yancey, MD, Medical Officer
To: Merck Research Laboratories (MRL)
Through: James P. Witter, MD, PhD, Medical Team Leader
Project Manager: Barbara J. Gould

Re: Label Negotiations: NDA19-853 505(b) (1), SLR-012  
Cuprimine capsules (d-penicillamine),  
MRL Letter Date: July 8, 2004

PRECAUTIONS, Geriatric Use Section;  
CLINICAL PHARMACOLOGY;  
CLINICAL PHARMACOLOGY, Pharmacokinetics

Re: Label Negotiations: NDA 019-853 505(b) (1), SLR-014  
MRL Letter Date: July 14, 2004

INDICATIONS, Wilson’s Disease;  
PRECAUTIONS, Pregnancy Category D

SLR-012
Reference is made to the supplemental New Drug Application for CUPRIMINE submitted on August 22, 2002 and to the HFD-550 Division’s October 8, 2003 Approvable Letter for this supplemental application which requested labeling changes. The sponsor sent an amendment to the supplemental application on April 23, 2004 with additional labeling changes. The HFD-550 Division sent additional labeling changes under the PRECAUTIONS, Geriatric Use section.

The Division recommended changes in the PRECAUTIONS, Geriatric Use Section based on literature review of CUPRIMINE in elderly patients compared to young patients. See the HFD-550 Fax communication to the sponsor dated June 16, 2004. (See Medical Officer Review, CUPRIMINE label dated June 14, 2004.)

MRL requested that the following sentence be removed from the revised label:
“Other reported clinical experience using penicillamine in the elderly, as compared to younger patients, identify proteinuria including nephritic syndrome, aplastic anemia, agranulocytosis, thrombocytopenia, low white blood cell count and gastrointestinal toxicities (e.g., abdominal pain, nausea, vomiting and diarrhea) more often in the elderly patients.”
The Division agreed with the sponsor’s request to remove this sentence from the label because each of the adverse events listed in this sentence are included in the ADVERSE EVENTS section of the CUPRIMINE label.

Subsequently, the sponsor sent a response (S-014) on July 8, 2004 to the Division’s Fax dated June 16, 2004, proposing an editorial change adding the letter “s” to the word “drug” in the last sentence of the first paragraph, Geriatric Use section.

“In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drugs.”

Comments
Adding the letter “s” to the word “drug” in the last sentence of the first paragraph, Geriatric Use Section, is acceptable to the HFD-550 Division.

CLINICAL PHARMACOLOGY
The sponsor added instructions for concomitant use with antacids, zinc or iron containing compounds.

“In all patients receiving penicillamine, it is important that CUPRIMINE be given on an empty stomach, at least one hour before meals or two hours after meals, and at least one hour apart from any other drug, food, milk, antacid, zinc or iron-containing preparation. This permits maximum absorption and reduces the likelihood of inactivation by metal binding in the gastrointestinal tract.”

Comments
The instructions for concomitant use with antacids, zinc or iron containing compounds is acceptable to the HFD-550 Division.

CLINICAL PHARMACOLOGY, Pharmacokinetics Section
The sponsor added instructions concerning metabolism and excretion to the text.

“More than 80% of plasma penicillamine is bound to proteins, especially albumin and ceruloplasmin. The drug also binds to erythrocytes and macrophages. A small fraction of the dose is metabolized in the liver to S-methyl-D-penicillamine. Excretion is mainly renal, mainly as disulfides.”

Comments
The instructions concerning metabolism and excretion are acceptable to the HFD-550 Division.

SLR-014
Reference is made to the November 11, 2003 letter from the HFD-550 Division which requested product labeling revisions to include sections providing Carcinogenesis, Mutagenesis, Impairment of Fertility and Pregnancy category information.

INDICATIONS, Wilson’s disease
The sponsor added an editorial change to incorporate a typographical correction to “Fleischer”.

Comments
The HFD-550 division accepts the corrected spelling of “Fleischer”.

NDA 19-853
d-penicillamine (CUPRIMINE)
Merck & Co., Inc.
PRECAUTIONS
The sponsor added text about the effect of penicillamine on fertility as per 21CFR 2-1.57(f)(5). A new subtitle was added, “Pregnancy”, “Pregnancy Category D” under the PRECAUTIONS section cross-referencing section “(see WARNINGS, Pregnancy)” as per 21CFR 201.57(f)(5). The changes submitted by the sponsor constitute a complete response to the HFD-550 Division’s request.

Two sentences have been added:
- “Penicillamine can cause fetal harm when administered to a pregnant woman” is added at the beginning of the “Pregnancy Category D” section.
- Another sentence has been added to the end of this section as, “If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus”.

Comments
These text additions are acceptable to the HFD-550 Division. See the Pharmacology/Toxicology Review by Concrad Chen, PhD.

Conclusions/Recommended Regulatory Actions:
The NDA 19-853/S-012 revisions in the PRECAUTIONS, Geriatric Use section, the CLINICAL PHARMACOLOGY and the CLINICAL PHARMACOLOGY, Pharmacokinetics section, are all acceptable to the HFD-550 Division.

The NDA 19-853/S-014 revisions in the INDICATIONS section and the WARNING, Pregnancy Category D section are acceptable to the HFD-550 Division.

_________________________________________
Carolyn L. Yancey, MD, Medical Officer

_________________________________________
James P. Witter, MD, PhD, Medical Team Leader
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Carolyn L. Yancey
8/27/04 03:19:16 PM
MEDICAL OFFICER

S-012 and S-014 Label CUPRIMINE

James Witter
8/27/04 05:03:55 PM
MEDICAL OFFICER
Concur
NDA number: 19,853
Serial number: S-014
Date received by Center: July 14, 2004
Date of review completion: August 20, 2004
Drug name: Cuprimine capsules (Penicillamine)
Indication: Wilson’s disease, cystinuria, and rheumatoid arthritis
Sponsor: Merck & Co.

Background: In a letter dated November 19, 2003, the Division requested the sponsor to revise nonclinical sections in the labeling for Cuprimine. In this submission, the sponsor provided several changes in labeling including Carcinogenesis, Mutagenesis, Impairment of Fertility, and Pregnancy. The sponsor states these changes constitute a complete response to the 11/19/03 FDA letter.

Review of the Labeling Changes:
In the Warning, the sponsor added Pregnancy Category D statement according to 21 CFR 201.57 (e) and (f)(6)(i)(d). One new sentence “Penicillamine can cause fetal harm when administered to a pregnant woman” is added at the beginning of the section. Another sentence “If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus” is added to the end of the section. The inclusion of these sentences is according to the standard format of Pregnancy D statement and it is acceptable.

The Pregnancy, Pregnancy Category D heading is added under the Precautions section. It also refers to the same information under the Warning. It is acceptable. Carcinogenesis, Mutagenesis, Impairment of Fertility section is added under Precautions. This is according to CFR 201.57 (f)(5) and is acceptable. New sentences regarding the mutagenicity findings and impairment of fertility are added to this section. The data are taken from the published literature submitted by the sponsor. The cited results from the Ames test, gene mutations in Chinese hamster V79 cells, sister chromatid exchanges and chromosome aberrations in cultivated mammalian cells have been reviewed and appeared correct. The proposed addition of mutagenesis section in the labeling is acceptable. However, since an in vivo genotoxicity test as recommended in ICH guideline has not been conducted for penicillamine, the updating of labeling with a new test is recommended.

Conrad H. Chen, Ph.D.
Reviewing Pharmacologist

Concurrence by: Josie Yang, Ph. D.
Pharmacology Team Leader
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Conrad Chen
8/24/04 10:08:01 AM
PHARMACOLOGIST
The labeling revisions are acceptable from the pharm/tox perspective.

Josie Yang
8/24/04 11:09:25 AM
PHARMACOLOGIST
APPLICATION NUMBER:
NDA 019853Orig1s014

OTHER REVIEW(S)
Division of Anesthesia, Analgesia and Rheumatology Products

REGULATORY PROJECT MANAGER REVIEW

Application Number: NDA 19-853/S-012
NDA 19-853/S-014

Name of Drug: CUPRIMINE™ (penicillamine) Capsules

Applicant: Merck & Co., Inc.

Material Reviewed:

Submission Date(s): January 26, 2005
Receipt Date(s): January 27, 2005

Background and Summary

Supplement S-012 was originally submitted by the applicant on August 22, 2002. The supplement was found to be approvable on October 8, 2003, and was resubmitted April 23, 2004. The supplement was approved on October 26, 2004.

Supplement S-014 was originally submitted on July 14, 2004. The supplement was approved on October 26, 2004.

The applicant submitted the Final Printed Labeling on January 26, 2005.

Review

The Final Printed Labeling is found to be identical to the labeling text specified in the FDA approval letter of October 26, 2004, and is acceptable.
Conclusions

An acknowledge and retain letter will be issued.

________________________________________
Barbara Gould
Regulatory Health Project Manager

Supervisory Comment/Concurrence:

________________________________________
Carolyn L. Yancey, MD
Medical Officer
CSO LABELING REVIEW
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Heather Jones
8/10/05 11:00:42 AM
SECRETARY

Parinda Jani
8/10/05 12:36:23 PM
CSO
APPLICATION NUMBER:
NDA 019853Orig1s014

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
NDA 19-853/S-014

PRIOR APPROVAL SUPPLEMENT

Merck & Co., Inc.
Attention: Kenneth A. Kramer
Manager, Regulatory Affairs
Sumneytown, Pike
P.O. Box 4, BLA-20
West Point, PA 19486

Dear Mr. Kramer:

We have received your supplemental new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Cuprimine™ (penicillamine) Capsules, 125 mg and 250 mg

NDA Number: 19-853

Supplement number: 014

Date of supplement: July 14, 2004

Date of receipt: July 15, 2004

This supplemental application proposes the following changes:

♦ WARNINGS, Pregnancy – adding category statement, Category D and pregnancy text elements referenced in 21 CFR 201.57(f)(6)(d);

♦ PRECAUTIONS, Carcinogenesis – revisions to “Carcinogenesis, Mutagenesis, Impairment of Fertility” and text about the mutagenic effect of penicillamine

♦ PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility and text about the mutagenic effect of penicillamine

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on September 15, 2004 in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be January 15, 2004.
All communications concerning this supplement should be addressed as follows:

**U.S. Postal Service:**
Food and Drug Administration  
Center for Drug Evaluation and Research  
Central Document Room  
5901-B Ammendale Rd.  
Beltsville, Md. 20705-1266

**Courier/Overnight Mail:**
Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Anti-Inflammatory, Analgesic,  
and Ophthalmic Drug Products, HFD-550  
Attention: Division Document Room, N115  
9201 Corporate Blvd.  
Rockville, Maryland 20850

If you have any question, call Barbara Gould, Regulatory Project Manager, at (301) 827-2506.

Sincerely,

/See appended electronic signature page/

Carmen DeBellas, R.Ph.  
Chief Project Management Staff  
Division of Anti-Inflammatory, Analgesic, &  
Ophthalmic Drug Products  
Office of Drug Evaluation V  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Barbara Gould
8/26/04 02:26:43 PM
for Mr. Carmen DeBellas, R.Ph.